CoChat

Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications

Open access
Levine, Deborah A., Langa, Kenneth M. · 2011 · Neurotherapeutics
Cited by 130

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

The prevalence of vascular cognitive impairment (VCI) is likely to increase as the population ages and cardiovascular disease survival improves. We provide an overview of the definition and disease mechanisms of VCI and present a systematic literature review of the current evidence for the pharmacologic and nonpharmacologic therapies used to treat the VCI symptoms of cognitive dysfunction or to modify VCI through primary and secondary prevention. The Cochrane Database of Systematic Reviews was searched from 2005 to October 2010 using the keywords “vascular dementia” or “vascular cognitive impairment and therapy.” MEDLINE was searched for English-language articles published within the last 10 years using the combined Medical Subject Headings (MeSH) “therapeutics and dementia,” “vascular” or “vascular cognitive impairment.” Although cholinesterase inhibitors and memantine produce small cognitive improvements in patients with VCI, these drugs do not improve global clinical outcomes and have adverse effects and costs. Selective serotonin reuptake inhibitors and dihydropyridine calcium channel blockers may improve short-term cognitive function in patients with VCI. Anti-hypertensive therapy with an ACE inhibitor-based regimen and statins may prevent the major subtype of VCI known as poststroke cognitive decline. Clinical and effectiveness studies with long-term follow-up are needed to determine the benefits and risks of pharmacologic and nonpharmacologic therapies to prevent and treat VCI. Given its growing health, social, and economic burden, the prevention and treatment of VCI are critical priorities for clinical care and research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13311-011-0047-z

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 85

  1. Lobo, 2000, Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S4
  2. He W, Sengupta M, Velkoff VA, DeBarros KA. U.S. Census Bureau, Current Population Reports, P23-209, 65+ in the United States: 2005, U.S. Government Printing Office,Washington, DC, 2005. · DOI
  3. Ukraintseva, 2006, Increasing rates of dementia at time of declining mortality from stroke, Stroke, 37, 1155, 10.1161/01.STR.0000217971.88034.e9 · DOI · Paper page
  4. Bowler, 1999, Conceptual background to vascular cognitive impairment, Alzheimer Dis Assoc Disord, 13, S30
  5. Rockwood, 2002, Societal costs of vascular cognitive impairment in older adults, Stroke, 33, 1605, 10.1161/01.STR.0000017878.85274.44 · DOI · Paper page
  6. Sicras, 2005, Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting, Dement Geriatr Cogn Disord, 19, 305, 10.1159/000084556 · DOI
  7. Hill, 2005, Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population, J Alzheimers Dis, 8, 43, 10.3233/JAD-2005-8105 · DOI · Paper page
  8. Boyle, 2004, Assessment and prediction of functional impairment in vascular dementia, Expert Rev Neurother, 4, 109, 10.1586/14737175.4.1.109 · DOI
  9. Nys, 2006, Early cognitive impairment predicts long-term depressive symptoms and quality of life after stroke, J Neurol Sci, 247, 149, 10.1016/j.jns.2006.04.005 · DOI · Paper page
  10. Fillit, 2002, The costs of vascular dementia: a comparison with Alzheimer's disease, J Neurol Sci, 203–204, 35, 10.1016/S0022-510X(02)00257-5 · DOI
  11. Knopman, 2003, Survival study of vascular dementia in Rochester, Minnesota, Arch Neurol, 60, 85, 10.1001/archneur.60.1.85 · DOI · Paper page
  12. Fitzpatrick, 2005, Survival following dementia onset: Alzheimer's disease and vascular dementia, J Neurol Sci, 229–230, 43, 10.1016/j.jns.2004.11.022 · DOI · Paper page
  13. Langa, 2004, Mixed dementia: emerging concepts and therapeutic implications, JAMA, 292, 2901, 10.1001/jama.292.23.2901 · DOI · Paper page
  14. Jin, 2006, The reciprocal risks of stroke and cognitive impairment in an elderly population, Alzheimers Dement, 2, 171, 10.1016/j.jalz.2006.03.006 · DOI · Paper page
  15. Knopman, 2009, Association of prior stroke with cognitive function and cognitive impairment: a population-based study, Arch Neurol, 66, 614, 10.1001/archneurol.2009.30 · DOI
  16. Tatemichi, 1993, Clinical determinants of dementia related to stroke, Ann Neurol, 33, 568, 10.1002/ana.410330603 · DOI · Paper page
  17. Desmond, 2002, Incidence of dementia after ischemic stroke: results of a longitudinal study, Stroke, 33, 2254, 10.1161/01.STR.0000028235.91778.95 · DOI · Paper page
  18. Desmond, 2000, Frequency and clinical determinants of dementia after ischemic stroke, Neurology, 54, 1124, 10.1212/WNL.54.5.1124 · DOI · Paper page
  19. Skoog, 1993, A population-based study of dementia in 85-year-olds, N Engl J Med, 328, 153, 10.1056/NEJM199301213280301 · DOI · Paper page
  20. Ahtiluoto, 2010, Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study, Neurology, 75, 1195, 10.1212/WNL.0b013e3181f4d7f8 · DOI · Paper page
  21. Hachinski, 2007, The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach, Stroke, 38, 1396, 10.1161/01.STR.0000260101.08944.e9 · DOI · Paper page
  22. Sachdev, 2004, The neuropsychological profile of vascular cognitive impairment in stroke and TIA patients, Neurology, 62, 912, 10.1212/01.WNL.0000115108.65264.4B · DOI · Paper page
  23. Roman, 2002, Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention, Med Clin North Am, 86, 477, 10.1016/S0025-7125(02)00008-1 · DOI
  24. Kivipelto, 2006, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study, Lancet Neurol, 5, 735, 10.1016/S1474-4422(06)70537-3 · DOI · Paper page
  25. Luchsinger, 2001, Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort, Am J Epidemiol, 154, 635, 10.1093/aje/154.7.635 · DOI · Paper page
  26. Ravaglia, 2008, Physical activity and dementia risk in the elderly: findings from a prospective Italian study, Neurology, 70, 1786, 10.1212/01.wnl.0000296276.50595.86 · DOI · Paper page
  27. Iadecola, 2003, Converging pathogenic mechanisms in vascular and neurodegenerative dementia, Stroke, 34, 335, 10.1161/01.STR.0000054050.51530.76 · DOI · Paper page
  28. Murray, 2009, The brain and the kidney connection: A model of accelerated vascular cognitive impairment, Neurology, 73, 916, 10.1212/WNL.0b013e3181b99a2e · DOI
  29. Honig, 2003, Stroke and the risk of Alzheimer disease, Arch Neurol, 60, 1707, 10.1001/archneur.60.12.1707 · DOI · Paper page
  30. Puccio, 2009, Atrial fibrillation and mild cognitive impairment: what correlation?, Minerva Cardioangiol, 57, 143
  31. Purandare, 2007, Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia, Biol Psychiatry, 62, 339, 10.1016/j.biopsych.2006.12.010 · DOI
  32. van Oijen, 2005, Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia, Stroke, 36, 2637, 10.1161/01.STR.0000189721.31432.26 · DOI · Paper page
  33. Yamamoto, 2005, High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia, J Am Geriatr Soc, 53, 583, 10.1111/j.1532-5415.2005.53204.x · DOI · Paper page
  34. Zuliani, 2007, High interleukin-6 plasma levels are associated with functional impairment in older patients with vascular dementia, Int J Geriatr Psychiatry, 22, 305, 10.1002/gps.1674 · DOI · Paper page
  35. Ivan, 2004, Dementia after stroke: the Framingham Study, Stroke, 35, 1264, 10.1161/01.STR.0000127810.92616.78 · DOI · Paper page
  36. Hebert, 2000, Vascular dementia : incidence and risk factors in the Canadian study of health and aging, Stroke, 31, 1487, 10.1161/01.STR.31.7.1487 · DOI · Paper page
  37. Kuller, 2003, Risk factors for dementia in the cardiovascular health cognition study, Neuroepidemiology, 22, 13, 10.1159/000067109 · DOI · Paper page
  38. Barba, 2000, Poststroke dementia: clinical features and risk factors, Stroke, 31, 1494, 10.1161/01.STR.31.7.1494 · DOI · Paper page
  39. Peters, 2005, Spectrum of mutations in biopsy-proven CADASIL: implications for diagnostic strategies, Arch Neurol, 62, 1091, 10.1001/archneur.62.7.1091 · DOI · Paper page
  40. Dotti, 2005, The spectrum of Notch3 mutations in 28 Italian CADASIL families, J Neurol Neurosurg Psychiatry, 76, 736, 10.1136/jnnp.2004.048207 · DOI · Paper page
  41. Tang, 2005, Arg332Cys mutation of NOTCH3 gene in the first known Taiwanese family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, J Neurol Sci, 228, 125, 10.1016/j.jns.2004.10.019 · DOI
  42. Leblanc, 2006, Genetics of vascular cognitive impairment: the opportunity and the challenges, Stroke, 37, 248, 10.1161/01.STR.0000195177.61184.49 · DOI
  43. Malouf, 2004, Donepezil for vascular cognitive impairment, Cochrane Database Syst Rev, 10.1002/14651858.CD004395.pub2 · DOI · Paper page
  44. Bores, 1996, Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine, J Pharmacol Exp Ther, 277, 728, 10.1016/S0022-3565(25)12928-5 · DOI · Paper page
  45. Maelicke, 2000, Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease, Eur J Pharmacol, 393, 165, 10.1016/S0014-2999(00)00093-5 · DOI · Paper page
  46. Craig, 2006, Galantamine for vascular cognitive impairment, Cochrane Database Syst Rev
  47. Craig, 2005, Rivastigmine for vascular cognitive impairment, Cochrane Database Syst Rev
  48. Gardoni, 2006, New targets for pharmacological intervention in the glutamatergic synapse, Eur J Pharmacol, 545, 2, 10.1016/j.ejphar.2006.06.022 · DOI
  49. Kornhuber, 1994, Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties, J Neural Transm Suppl, 43, 91
  50. Qaseem, 2008, Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians, Ann Intern Med, 148, 370, 10.7326/0003-4819-148-5-200803040-00008 · DOI · Paper page
  51. O'Brien JT, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol published online 18 November 2010. 10.1177/0269881110387547. The online version of this article can be found at: http://jop.sagepub.com/content/early/2010/11/17/0269881110387547 · DOI · Paper page
  52. Wong, 2009, Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia, Can J Neurol Sci, 36, 735, 10.1017/S0317167100008350 · DOI
  53. Meyer, 1986, Improved cognition after control of risk factors for multi-infarct dementia, JAMA, 256, 2203, 10.1001/jama.1986.03380160061021 · DOI · Paper page
  54. Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch Intern Med, 163, 1069, 10.1001/archinte.163.9.1069 · DOI · Paper page
  55. Bosch, 2002, Use of ramipril in preventing stroke: double blind randomised trial, BMJ, 324, 699, 10.1136/bmj.324.7339.699 · DOI · Paper page
  56. Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial, J Hypertens, 21, 875, 10.1097/00004872-200305000-00011 · DOI · Paper page
  57. Diener, 2008, Lancet Neurol, 7, 875, 10.1016/S1474-4422(08)70198-4 · DOI · Paper page
  58. Qiu, 2005, The age-dependent relation of blood pressure to cognitive function and dementia, Lancet Neurol, 4, 487, 10.1016/S1474-4422(05)70141-1 · DOI · Paper page
  59. Wang, 2009, Blood Pressure and Brain Injury in Older Adults: Findings from a Community-Based Autopsy Study, J Am Geriatr Soc, 57, 1975, 10.1111/j.1532-5415.2009.02493.x · DOI · Paper page
  60. Lopez-Arrieta, 2002, Nimodipine for primary degenerative, mixed and vascular dementia, Cochrane Database Syst Rev
  61. Moretti, 2008, Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia, Am J Alzheimers Dis Other Demen, 23, 167, 10.1177/1533317507312558 · DOI
  62. Broe, 2000, Anti-inflammatory drugs protect against Alzheimer disease at low doses, Arch Neurol, 57, 1586, 10.1001/archneur.57.11.1586 · DOI · Paper page
  63. Meyer, 1989, Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study, J Am Geriatr Soc, 37, 549, 10.1111/j.1532-5415.1989.tb05688.x · DOI · Paper page
  64. Williams, 2000, Aspirin for vascular dementia, Cochrane Database Syst Rev
  65. Dufouil, 2005, APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study, Neurology, 64, 1531, 10.1212/01.WNL.0000160114.42643.31 · DOI · Paper page
  66. Moroney, 1999, Low-density lipoprotein cholesterol and the risk of dementia with stroke, JAMA, 282, 254, 10.1001/jama.282.3.254 · DOI · Paper page
  67. Collins, 2004, Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions, Lancet, 363, 757, 10.1016/S0140-6736(04)15690-0 · DOI · Paper page
  68. Richard, 2009, Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial, J Am Geriatr Soc, 57, 797, 10.1111/j.1532-5415.2009.02217.x · DOI · Paper page
  69. Richard, 2009, Moll van Charante EP, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress, Alzheimer Dis Assoc Disord, 23, 198, 10.1097/WAD.0b013e31819783a4 · DOI · Paper page
  70. Fioravanti, 2005, Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly, Cochrane Database Syst Rev, 10.1002/14651858.CD000269.pub3 · DOI · Paper page
  71. Cohen, 2003, Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: neuroimaging and neuropsychological outcomes, Cerebrovasc Dis, 16, 199, 10.1159/000071116 · doi:10.1159/000071116
  72. Alvarez-Sabin, 2011, Citicoline in vascular cognitive impairment and vascular dementia after stroke, Stroke, 42, S40, 10.1161/STROKEAHA.110.606509 · DOI
  73. Olin, 2001, Hydergine for dementia, Cochrane Database Syst Rev
  74. Napryeyenko, 2007, Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial, Arzneimittelforschung, 57, 4
  75. Hao, 2009, Huperzine A for vascular dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD007365.pub2 · DOI
  76. Frampton, 2003, Propentofylline for dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD002853 · DOI · Paper page
  77. Banasr, 2004, Serotonin-induced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone, Neuropsychopharmacology, 29, 450, 10.1038/sj.npp.1300320 · DOI · Paper page
  78. Royall, 2009, Sertraline improves executive function in patients with vascular cognitive impairment, J Neuropsychiatry Clin Neurosci, 21, 445, 10.1176/jnp.2009.21.4.445 · DOI · Paper page
  79. De Rango, 2008, The role of carotid artery stenting and carotid endarterectomy in cognitive performance: a systematic review, Stroke, 39, 3116, 10.1161/STROKEAHA.108.518357 · DOI
  80. Rockwood, 2007, Physical activity and the maintenance of cognitive function, Alzheimers Dement, 3, S38, 10.1016/j.jalz.2007.01.003 · DOI · Paper page
  81. Quaney, 2009, Aerobic exercise improves cognition and motor function poststroke, Neurorehabil Neural Repair, 23, 879, 10.1177/1545968309338193 · DOI · Paper page
  82. Friedman, 1988, CARDIA: study design, recruitment, and some characteristics of the examined subjects, J Clin Epidemiol, 41, 1105, 10.1016/0895-4356(88)90080-7 · DOI · Paper page
  83. Hajjar, 2009, The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition, BMC Geriatr, 9, 48, 10.1186/1471-2318-9-48 · DOI · Paper page
  84. Williamson, 2007, The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods, Am J Cardiol, 99, 112i, 10.1016/j.amjcard.2007.03.029 · DOI
  85. Frisoni, 2007, Prescription patterns and efficacy of drugs for patients with dementia: physicians' perspective in Italy, Aging Clin Exp Res, 19, 349, 10.1007/BF03324714 · DOI

Cited by

See all 130

Metadata

Authors
Levine, D. A., & Langa, K. M.
Venue
Neurotherapeutics
Publisher
Elsevier BV
Published
2011-07
Volume
8
Issue
3
Pages
361-373
ISSN
1878-7479 (ISSN-L)
OpenAlex
W2082094370
Cited by
130
References
56
FWCI
7.29
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. https://app.cochat.ai/papers/10.1007/s13311-011-0047-z
The paper
Levine, D. A., & Langa, K. M. (2011). Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. Neurotherapeutics. https://doi.org/10.1007/s13311-011-0047-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.